Miricorilant + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antipsychotic-induced Weight Gain (AIWG)
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Trial Timeline
Dec 4, 2019 → Jul 6, 2022
NCT ID
NCT03818256About Miricorilant + Placebo
Miricorilant + Placebo is a phase 2 stage product being developed by Corcept Therapeutics for Antipsychotic-induced Weight Gain (AIWG). The current trial status is completed. This product is registered under clinical trial identifier NCT03818256. Target conditions include Antipsychotic-induced Weight Gain (AIWG).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03823703 | Phase 2 | Terminated |
| NCT03818256 | Phase 2 | Completed |
Competing Products
2 competing products in Antipsychotic-induced Weight Gain (AIWG)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Olanzapine + CORT118335 + Placebo | Corcept Therapeutics | Phase 1 | 28 |